Why the study?
Does interferon treatment impair thrombopoietin synthesis in human hepatic cell cultures?
Does interferon treatment impair thrombopoietin synthesis in human hepatic cell cultures?
Interferon therapy likely causes thrombocytopenia through effects on megakaryocytic cells and platelets rather than by impairing hepatic thrombopoietin synthesis.
Answers are grounded in this paper and cite their sources.
IFN therapy thrombocytopenia unlikely from hepatic TPO suppression; leaves open megakaryocyte/platelet effects in humans.
Thrombocytopenia is an important complication of interferon (IFN) therapy for chronic viral hepatitis. To study whether IFN interferes with hepatic thrombopoietin (TPO) synthesis, we used the human hepatoma cell line HepG2. Our results show that IFN-alpha, IFN-beta, or IFN-gamma did not impair TPO mRNA expression, as determined by quantitative RT-PCR, even when high IFN doses (up to 5000 U/ml) or long-term incubations (up to 14 days) were applied. Neither was the rate of secretion of immunoreactive TPO reduced on IFN treatment. These findings support the concept that IFNs primarily mediate effects on megakaryocytic cells and platelets rather than on TPO-producing hepatocytes.
No takes yet. Share an insight, caveat, or question.
Wolber et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: